Nine facilities in northern California region named Centers of Excellence in accelerated partial breast irradiation

NewsGuard 100/100 Score

Nine facilities in the northern California region have been named Centers of Excellence in accelerated partial breast irradiation (APBI) for their use of the SAVI® applicator, an advanced therapy for breast cancer as part of breast conservation therapy. The SAVI applicator can provide important advantages for women with early-stage breast cancer.

“Cianna Medical is proud to acknowledge the contributions these surgeons and radiation oncologists are making to the APBI field”

The Center of Excellence designation recognizes these facilities' dedication to education, training and experience in APBI. To qualify, physicians, medical physicists and clinical staff were required to complete a comprehensive training and education program to demonstrate proficiency in delivering radiation therapy with SAVI. The facilities have also expressed a commitment to patient education, advocacy and awareness of advanced breast cancer treatments.

"Cianna Medical is proud to acknowledge the contributions these surgeons and radiation oncologists are making to the APBI field," said Jill Anderson, President and CEO of Cianna Medical. "They are changing how we care for women with early-stage breast cancer by recognizing the clinical benefits of more targeted radiation therapy and choosing to make it available to their patients."

Centers and physicians receiving the designation were:
 
Mills Peninsula Hospital in San Mateo, CA
Surgeon: Andrea Metkus, MD, and Lora Hebert, MD
 
Good Samaritan Hospital in Los Gatos, CA
 
El Camino Hospital in Mountain View, CA
Surgeon: Peter Naruns, MD
 
Valley Medical Oncology Consultants in Pleasanton, CA
 
Renown Institute for Cancer in Reno, NV
Surgeon: Frieda Hulka, MD

The commitment of these centers and physicians to offer the SAVI applicator extends the benefits of breast conservation therapy to a larger group of women and results in improved clinical outcomes.

Breast conservation therapy includes lumpectomy- the surgical removal of the cancerous tissue within the breast plus tissue immediately around the tumor - followed by radiation. This approach is an alternative to mastectomy, which removes the entire breast and is often followed by breast reconstruction.

The SAVI applicator delivers a form of radiation therapy known as breast brachytherapy. This approach, which targets the tumor site from inside the breast, is becoming a more widely used alternative to traditional radiation.

Breast brachytherapy typically involves two treatments per day for only five days. This shorter timeframe makes brachytherapy far more convenient than traditional, external-beam radiation. The latter is delivered five times a week and takes six or seven weeks.

Radiation treatment after a lumpectomy has traditionally involved irradiation of the entire breast with an external beam. Besides the inconvenience of the six-week-long regimen, many women must travel some distance to receive external-beam radiation. That can put additional stress on their families, jobs, and financial resources.

In addition to shortening the therapy time, breast brachytherapy with SAVI minimizes radiation exposure of healthy tissue, which reduces damage to critical structures such as the skin, heart, lungs and ribs.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis